Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome

Introduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacter...

Full description

Bibliographic Details
Main Authors:	Ramos, R., Lopes, F., Rodrigues, T., Rolim, N., Rodrigues, I., Monteiro, H.
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657421/

id	pubmed-3657421
recordtype	oai_dc
spelling	pubmed-36574212013-06-04 Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome Ramos, R. Lopes, F. Rodrigues, T. Rolim, N. Rodrigues, I. Monteiro, H. Case Report Introduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteria. Cancer associated HUS is uncommon, and there are only scarce reports on prostate cancer presenting with HUS. Case Presentation. A 72-year-old man presented to the emergency department with oliguria, hematuria, and hematemesis. Clinical evaluation revealed acute renal failure, hemolysis, normal blood-clotting studies, and prostate-specific antigen value of 1000 ng/mL. The patient was started on hemodialysis, ultrafiltration with plasma exchange, and androgen blockade with bicalutamide and completely recovered from HUS. The authors review the 14 published cases on this association. Conclusion. The association of HUS and prostate cancer occurs more frequently in patients with high-grade, clinically advanced prostate cancer. When readily recognized and appropriately treated, HUS does not seem to worsen prognosis in prostate cancer patients. Hindawi Publishing Corporation 2013 2013-04-30 /pmc/articles/PMC3657421/ /pubmed/23738188 http://dx.doi.org/10.1155/2013/459618 Text en Copyright © 2013 R. Ramos et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Ramos, R. Lopes, F. Rodrigues, T. Rolim, N. Rodrigues, I. Monteiro, H.
spellingShingle	Ramos, R. Lopes, F. Rodrigues, T. Rolim, N. Rodrigues, I. Monteiro, H. Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
author_facet	Ramos, R. Lopes, F. Rodrigues, T. Rolim, N. Rodrigues, I. Monteiro, H.
author_sort	Ramos, R.
title	Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_short	Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_full	Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_fullStr	Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_full_unstemmed	Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome
title_sort	advanced prostate cancer presenting as hemolytic uremic syndrome
description	Introduction. Hemolytic uremic syndrome (HUS) is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteria. Cancer associated HUS is uncommon, and there are only scarce reports on prostate cancer presenting with HUS. Case Presentation. A 72-year-old man presented to the emergency department with oliguria, hematuria, and hematemesis. Clinical evaluation revealed acute renal failure, hemolysis, normal blood-clotting studies, and prostate-specific antigen value of 1000 ng/mL. The patient was started on hemodialysis, ultrafiltration with plasma exchange, and androgen blockade with bicalutamide and completely recovered from HUS. The authors review the 14 published cases on this association. Conclusion. The association of HUS and prostate cancer occurs more frequently in patients with high-grade, clinically advanced prostate cancer. When readily recognized and appropriately treated, HUS does not seem to worsen prognosis in prostate cancer patients.
publisher	Hindawi Publishing Corporation
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657421/
_version_	1611978860736282624

Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome

Similar Items